Last reviewed · How we verify

NCT03050333

Efficacy and Safety of Endoscopic Resection

Status unknown Last updated 10 February 2017
What this trial tests

trial in Endoscopic Resection in 3,000 participants. Status unknown.

Timeline
25 April 2013
Primary endpoint
31 December 2022
31 December 2023

Quick facts

Lead sponsorEDUARDO ALBENIZ
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment3,000
Start date25 April 2013
Primary completion31 December 2022
Estimated completion31 December 2023
Sites1 location across Spain

Conditions studied

Sponsor

EDUARDO ALBENIZ

Who can join

18 and older, any sex, with Endoscopic Resection or Gastrointestinal Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An observational, prospective, multicentre and international study. This will be a non-interventional study to evaluate the efficacy and safety of endoscopic resection of gastrointestinal lesions and to determine what are the factors related to complications, and to describe these lesions according to the different morphologic and histologic classifications.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Clinical validation of risk scoring systems to predict risk of delayed bleeding after EMR of large colorectal lesions.
    Albéniz E, Gimeno-García AZ, Fraile M, Ibáñez B, et al · · 2020 · cited 33× · PMID 31655045 · DOI 10.1016/j.gie.2019.10.013

Verify or expand the search:

Other EDUARDO ALBENIZ trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03050333.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing